COVID-19 or other serious viral infections may “reprogram” immune cells in the lungs to facilitate development and growth of lung cancer, even years afterward. (UVA Health)
Stirring the pot in a longstanding controversy, a new study showed higher cancer mortality in both sexes across multiple age groups for people living in proximity to nuclear power plants. (Nature Communications)
The selective estrogen receptor degrader giredestrant plus palbociclib (Ibrance) did not significantly improve progression-free survival (PFS) in advanced hormone receptor-positive/HER2-negative breast cancer versus letrozole and palbociclib in a phase III trial, Genentech announced.
The FDA announced plans to ease certain requirements on the approval path for biosimilars in an effort to get more lower priced biologics to market quicker.
In the TV series “After Life,” comedian Ricky Gervais portrayed a man whose wife had died of cancer, and now his long-time partner, Jane Fallon, has disclosed that she has breast cancer. (People)
A 22-year-old woman from Philadelphia had severe neck and ear pain every time she drank alcohol, symptoms that turned out to be related to Hodgkin lymphoma. (People)
The FDA granted premarket approval to the first artificial intelligence-informed imaging device for breast cancer surgery, Perimeter Medical Imaging announced.
New evidence that geography, race, and insurance status not only influence the risk of breast cancer but also the stage at diagnosis. (American College of Surgeons)
Results from preclinical studies suggest the dietary supplement β-hydroxybutyrate, a metabolite of a ketogenic diet, may enhance the anticancer potential of chimeric antigen receptor (CAR) T-cell therapy. (Cell)
Other preclinical studies showed that CAR T-cell therapy after surgery or radiation therapy reduced residual cancer burden and the risk of metastasis. (Houston Methodist)
A sweet solution for triple-negative breast cancer? Naturally occurring compounds in dark sweet cherries appeared to slow the growth of cancer xenografts in laboratory animals. (Texas A&M AgriLife)
Combination therapy including the investigational protein degrader mezigdomide led to a significant PFS improvement in relapsed/refractory multiple myeloma versus carfilzomib (Kyprolis) and dexamethasone in a phase III trial, Bristol Myers Squibb announced.
Source link : https://www.medpagetoday.com/hematologyoncology/othercancers/120300
Author :
Publish date : 2026-03-13 17:56:00
Copyright for syndicated content belongs to the linked Source.
